Ascendis Pharma bags YORVIPATH FDA approval for adult hypoparathyroidism

Ascendis Pharma bags YORVIPATH FDA approval for adult hypoparathyroidism

In a landmark decision, the U.S. Food and Drug Administration (FDA) has granted approval to Ascendis Pharma A/S’s YORVIPATH (palopegteriparatide), making it the first and only treatment specifically for adult hypoparathyroidism. This rare endocrine disorder, characterised by insufficient levels of parathyroid hormone, affects between 70,000 to 90,000 people across the United States. YORVIPATH, developed under […]

AstraZeneca to acquire Amolyt Pharma in $1.05bn deal to expand rare disease portfolio

AstraZeneca to acquire Amolyt Pharma in $1.05bn deal to expand rare disease portfolio

AstraZeneca has announced a definitive agreement to acquire Amolyt Pharma, a clinical-stage biotechnology company focused on novel treatments for rare endocrine diseases, in a deal valued at up to $1.05 billion. This acquisition is poised to strengthen the late-stage pipeline of Alexion, AstraZeneca Rare Disease, particularly bolstering its bone metabolism franchise through the addition of […]